Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-14T19:37:27.492Z Has data issue: false hasContentIssue false
  • English
  • Français

Are Levodopa “Drug Holidays” Justified?

Published online by Cambridge University Press:  18 September 2015

Oscar S. Kofman
Oscar S. Kofman*
Affiliation:
Department of Medicine (Neurology), University of Toronto, and Mt. Sinai Hospital, Toronto
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Complete withdrawal of all levodopa compounds “drug holiday” for a period of at least one week in severely disabled, unresponsive Parkinson patients may influence receptor blockade by resensitizing and can alter denervation hypersensitivity.

Twenty four patients with 31 holidays were evaluated. Transient improvement was noted in most patients, however significant long term benefit of over 1 years duration occurred in only 6 individuals.

In view of the unpredictability and limited responsiveness, drug holiday has not yet been established as a satisfactory treatment for the severe, intractable problems associated with chronic levodopa administration in Parkinson patients. Further trials appear to be warranted.

Type
7. Treatment of Parkinson’s Disease
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue S1: Current Concepts and Controversies in Parkinson’s Disease , February 1984 , pp. 206 - 209
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Barbeau, A, McDowell, FH (eds.) (1970) L-Dopa and Parkinsonism, 343–407. FA Davis Co. Phila.Google Scholar
DeJong, RN.Currier, RD (1982) Year Book of Neurology and Neurosurgery. Year Book Medical Publishers, Chicago. 154.Google Scholar
Direnfeld, L, Spiro, L, Marotta, J.Seeman, P (1978) The L-dopa on-off effect of Parkinson’s disease: Treatment by transient drug withdrawal and dopamine receptor sensitization. Ann. Neurol. 4:473–475.CrossRefGoogle Scholar
Goetz, C, Tanner, C, Klawans, HL (1982) Drug Holiday in the Management of Parkinson’s Disease. Clinical Neurology. 5: No. 4:351–364.Google Scholar
Kofman, O (1971) Treatment of Parkinson’s Disease with L-dopa. Can. Med. Assoc. J: 104:483–487.Google ScholarPubMed
Kofman, O (1982) Drug Holiday in Parkinson’s disease – A Long Term Appraisal, Abstracts 17th Congress of Neurological Sciences. Can. J. Neurol. Sci. 9:273.Google Scholar
Kofman, O (1983) Complications of Therapy in Parkinson’s disease. Can. Fam. Physician 29:87–91.Google ScholarPubMed
Koller, WC (1982) Alternate Day Levodopa Therapy in Parkinsonism, Neurology, 32:324–326.CrossRefGoogle ScholarPubMed
Koller, WC, Weiner, WD, Klawans, HLet al. (1982) Complications of Chronic Levodopa Therapy: Long Term Efficiency of Drug Holiday. Neurology 31:473–476.CrossRefGoogle Scholar
Marsden, CD.Parkes, JA (1976) On-Off Effects with Parkinson’s disease on Chronic Levodopa Therapy, Lancet 1: 292–295.CrossRefGoogle ScholarPubMed
Marsden, CD (1981) Bromocriptine in Parkinson’s Disease. Research and Clinical Forums, Tunbridge Wells. England 3: No. 2:24–27.Google Scholar
Mullen, P, Seeman, P (1979) Pre-synaptic Subsensitivity as a Possible Basis For Sensitization by Long Term Dopamine Mimetics, Eur. J. Pharacol. 55:149–157.CrossRefGoogle Scholar
Ptcoch, CJ, Marsden, CD (1977) Central Dopaminergic Receptor Supersensitivity and its Relevance to Parkinson’s Disease, J. Neurol. Sci. 31:113–131.Google Scholar
Rinne, VK (1980) Recent Advances in the Treatment of Parkinson’s Disease, ACTA Nevol Scand. 62:103–121.CrossRefGoogle Scholar
Sweet, RD, Lee, JE, Spiegel, HE, McDowell, F (1972) Enhanced Response to Low Doses of Levodopa After Withdrawal from Chronic Treatment. Neurology 22:520–525.CrossRefGoogle ScholarPubMed
Weiner, WJ, Perlik, S, Koller, WC, Nausieda, PA, Klawans, HL (1980) The Role of Drug Holiday in the Management of Parkinson’s Disease. Neurology 30:1257–1261.CrossRefGoogle Scholar
Yahr, MD (1978) Overview of Present Day Treatment of Parkinson’s Disease. J. Neural. Transm. 43:227–238.CrossRefGoogle ScholarPubMed